What is the best treatment approach for an 83-year-old male with metastatic prostate cancer diagnosed by Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) scan?

Treatment Approach for an 83-Year-Old Male with Metastatic Prostate Cancer Detected by PSMA PET

For an 83-year-old male with metastatic prostate cancer detected by PSMA PET, androgen deprivation therapy (ADT) should be the primary treatment, with consideration of adding an AR pathway inhibitor (apalutamide, enzalutamide, or darolutamide) based on the extent and risk of metastatic disease. 1

Initial Assessment

• Assess the extent of metastatic disease (lymph node, bone, and visceral metastases) using the PSMA PET findings 1
• Determine if the patient has high-volume or high-risk metastatic disease:
  • High-volume: presence of visceral metastases and/or ≥4 bone metastases with at least one outside the vertebral column and pelvis 1
  • High-risk: presence of two of three high-risk features: Gleason ≥8, ≥3 bone lesions, or measurable visceral metastases 1

Treatment Algorithm

First-Line Treatment: ADT

• Medical castration with LHRH agonist or antagonist is the standard first-line therapy 1, 2
• Surgical castration (orchiectomy) is an alternative option but less commonly used 2
• Early initiation of ADT upon diagnosis of metastatic disease is standard practice due to lower incidence of severe adverse events including cord compression 2

Additional Therapy Based on Disease Burden

1. For high-volume or high-risk metastatic disease:

   • ADT plus an AR pathway inhibitor (apalutamide, enzalutamide, or darolutamide) is recommended 1
   • Consider docetaxel chemotherapy only if the patient has excellent performance status and minimal comorbidities, as age >75 requires close monitoring for toxicity 3

2. For low-volume or low-risk metastatic disease:

   • ADT alone may be sufficient, especially considering the patient's advanced age 1
   • If the patient has good performance status, adding an AR pathway inhibitor may provide additional benefit 1

PSMA-Targeted Therapy Considerations

• If the patient progresses to castration-resistant prostate cancer, 177Lu-PSMA-617 therapy may be considered if:
  • The patient has confirmed PSMA-positive metastatic lesions without dominant PSMA-negative lesions 4
  • Previous treatments have failed 4
  • Homogeneous PSMA expression is present across all lesions 4

Monitoring and Follow-up

• Obtain serial PSA measurements at 3-6 month intervals 1
• Calculate PSA doubling time (PSADT) to assess disease progression 1
• Perform conventional imaging (CT, MRI, bone scan) at 6-12 month intervals to assess for disease progression 1
• Consider repeat PSMA PET imaging if there is biochemical progression to guide subsequent treatment decisions 1, 5

Important Considerations for Elderly Patients

• Elderly patients (>65 years) treated with docetaxel have higher rates of adverse events including diarrhea (55%), infections (42%), peripheral edema (39%), and stomatitis (28%) 3
• Quality of life considerations are paramount in this age group, as ADT can cause significant hormone-related symptoms 1
• Continuous ADT remains the standard of care for metastatic disease based on survival outcomes, though intermittent ADT may be considered in selected patients with significant quality of life concerns 2

Pitfalls to Avoid

• Do not rely solely on PSA response to guide treatment decisions, as PSMA expression can show a "flare phenomenon" after initiation of AR-targeted therapy, which does not indicate disease progression 6
• Avoid aggressive chemotherapy in elderly patients with significant comorbidities due to increased risk of toxicity 3
• Be cautious with interpretation of PSMA PET findings, as lower PSA levels with high PSMA-TV (total tumor volume) may indicate tumor dedifferentiation and worse prognosis 7